{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT02621151","nct_id":"NCT02621151","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02621151. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"* Lead-in single dose Pembrolizumab 200 mg, intravenously (IV)\n* Transurethral Resection of Bladder Tumor (TURBT) at pre-RT (maximal) and completion of therapy (diagnostic)\n* External Beam Radiation Therapy (EBRT) - 52 Gy in 20 fractions over 4 weeks (1 fraction = 2.6 Gy)\n* Gemcitabine 27 mg/m\\^2 IV twice weekly for 4 weeks concurrent with EBRT\n* Pembrolizumab 200 mg IV every 3 weeks for total 3 doses starting day 1 of EBRT","label":"Pembrolizumab, Gemcitabine, and RT","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2025-12-15","type":"ACTUAL"},"conditions":["Muscle-invasive Urothelial Cancer of the Bladder"],"enrollment":{"count":60,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pembrolizumab","otherNames":["MK3475","Keytruda"],"type":"BIOLOGICAL"},{"name":"Transurethral Resection of Bladder Tumor","otherNames":[],"type":"PROCEDURE"},{"name":"Gemcitabine","otherNames":["Gemzar"],"type":"DRUG"},{"name":"External Beam Radiation Therapy","otherNames":[],"type":"RADIATION"}],"last_update":"2026-09-30","lead_sponsor":"NYU Langone Health","official_title":"A Phase II Trial of MK3475 in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-11-10","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants Who Achieved Two-year Bladder-intact Disease-free Survival","timeFrame":"2 years"}],"references":[],"start_date":{"date":"2016-08-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder","url":"https://clinicaltrials.gov/study/NCT02621151"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02621151"}